Cizzle Biotechnology - Patent Granted in USA
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR")
12 June 2026
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Patent Granted in USA
Cizzle Biotechnology, the UK-based developer of diagnostic tests for early-stage cancer, is pleased to announce that a patent application covering the Company's core methods to measure the CIZ1B lung cancer biomarker has now been allowed by the U.S. Patent and Trademark Office ("USPTO"). This additional patent further enhances the Company's strong patent portfolio, especially in the key market of the USA and follows the grant of a patent in Canada, as announced on 4 February 2026.
As with the recent patent granted in Canada, the USPTO patent, 'Use of a fibrinogen capture agent to detect a CIZ1B variant', concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc ("BIO") for use in North America and the Caribbean, and these new patents strengthen BIO's position as they prepare to launch the test and establish a robust position for commercialising the Company's innovative and proprietary technology.
Background
The CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York, initially supported by both UK industry and charity sector research grants.
The Company's commercial strategy is to licence globally its proprietary test for the CIZ1B biomarker for use in the early detection of lung cancer. As such, Cizzle Biotechnology's patent portfolio and technology know-how is central to securing future licensing and royalty revenue. Developing a strong patent portfolio in North America is intended to enable BIO to establish a leading market position and supports its partnership programme with specialist clinical laboratories and hospitals, enabling market penetration to ensure the test is available to as many clinicians and patients as possible.
Cizzle Biotechnology also has been granted patent protection from the European Patent Office and intends to secure further licensing partnerships with accredited facilities in the UK and Europe, including the NHS. Bringing the CIZ1B biomarker test to market will provide valuable new solutions applicable to the current NHS cancer plan which aims to improve cancer survival by diagnosing 75% of cancers at stages 1 and 2 by 2028.
Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said:
"Strengthening of the Company's patent portfolio with this grant by the USPTO is timely and perfectly aligned with recent efforts to take the CIZ1B ELISA test format to market with our US partner Cizzle Bio Inc."
Enquiries:
Cizzle Biotechnology Holdings plc
Via IFC Advisory
Allan Syms (Executive Chairman)
Allenby Capital Limited
+44(0) 20 3328 5656
John Depasquale (Corporate Finance)
Amrit Nahal (Sales and Corporate Broking)
IFC Advisory Limited
+44(0) 20 3934 6632
Tim Metcalfe
Florence Staton
About Cizzle Biotechnology
The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDMSCUAVBRNVUNAAR
